Description
The study shows both neuroinflammation and protein aggregation patterns but doesn’t explain their mechanistic relationship. Understanding whether microglia activation drives pathology spread or vice versa is critical for therapeutic targeting.
Gap type: unexplained_observation Source paper: In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. (2021, Journal of neurology, neurosurgery, and psychiatry, PMID:33122395)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:24.529613+00:00”, “resolution_summary”: “Resolved by hypothesis h-72c719461c: C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-72c719461c”, “title”: “C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD”, “score”: 0.425, “reason”: “8 token overlaps; entity overlap: ftd, tdp-43”, “analysis_id”: “test-hypothesis-fixtures-v1”, “target_gene”: “C9orf72”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“21944792”, “28960178”, “29460270”, “39605053”, “40520109”]}, {“id”: “h-var-a0933e666d”, “title”: “Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD”, “score”: 0.334, “reason”: “17 token overlaps; entity overlap: ftd, tdp-43”, “analysis_id”: “SDA-2026-04-01-gap-20260401-225149”, “target_gene”: “AIM2, CASP1, IL1B, PYCARD, TARDBP”, “target_pathway”: “Microglial AIM2 inflammasome activation via phagocytosed neuron-derived mtDNA in TDP-43 proteinopathy”, “disease”: “neurodegeneration”, “composite_score”: 0.8240000000000001, “confidence_score”: 0.76, “status”: “proposed”, “pubmed_evidence_ids”: [“27519954”, “28506519”, “29263430”, “29643512”, “30610225”]}, {“id”: “h-530326b97069”, “title”: “SASP-Secreted MMP-9 from Senescent Microglia Generates Pathological TDP-43 C-Terminal Fragments That Propagate ALS Pathology”, “score”: 0.231, “reason”: “8 token overlaps; entity overlap: tdp-43”, “analysis_id”: “SDA-2026-04-26-gap-20260425215446”, “target_gene”: “MMP9 → TARDBP (C-terminal fragments) → cytoplasmic aggregation seeding”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.713424, “confidence_score”: 0.3, “status”: “proposed”, “pubmed_evidence_ids”: [“21209826”, “30458231”, “33300249”, “39067491”]}, {“id”: “h-alsmnd-54f981ca6a25”, “title”: “TIA1 Low-Complexity Domain Oxidation Drives Aberrant Stress Granule Assembly and TDP-43 Mislocalization in ALS Motor Neurons”, “score”: 0.23, “reason”: “8 token overlaps; entity overlap: tdp-43”, “analysis_id”: null, “target_gene”: “TIA1,TDP-43,TARDBP,G3BP1,MAPK1,Oxidative stress response”, “target_pathway”: null, “disease”: “ALS”, “composite_score”: 0.81, “confidence_score”: 0.75, “status”: “open”, “pubmed_evidence_ids”: [“23092511”, “34378050”, “34750982”, “36499097”]}, {“id”: “h-183fff58”, “title”: “TDP-43 Pathology Disrupts the HGS-PYGB Autophagy Receptor Cascade in Motor Neurons”, “score”: 0.229, “reason”: “5 token overlaps; entity overlap: tdp-43”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “target_gene”: “TARDBP (TDP-43), HGS, PYGB”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.7030000000000001, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“19023281”, “28760759”, “29417807”, “29507358”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf_task_9aae8fc5”, “title”: “TDP-43 inclusions occur in AD, ALS, and FTLD but the pathogenic mechanisms leading to TDP-43 pathology may differ between diseases. Understanding disease-specific drivers could reveal why TDP-43 shows limbic distribution in AD versus other patterns in ALS/FTLD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.581, “reason”: “11 token overlaps; entity overlap: pmid, tdp-43”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-094b44bf”, “quality_score”: 0.697, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.539, “reason”: “10 token overlaps; entity overlap: pmid, tdp-43”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.537, “reason”: “9 token overlaps; entity overlap: pmid, tdp-43”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018_task_73907230”, “title”: “The study identifies cGAS/STING activation as a consequence of TDP-43-mediated mtDNA release, but the temporal dynamics and whether this pathway drives chronic inflammation or acute toxicity remains unclear. This distinction is critical for determining therapeutic timing and approach.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.504, “reason”: “10 token overlaps; entity overlap: pmid, tdp-43”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018”, “quality_score”: 0.73, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046_task_9aae8fc5”, “title”: “While the study establishes TDP-43 triggers mtDNA release via mPTP to activate cGAS/STING, it’s unclear why this pathway preferentially affects motor neurons in ALS when TDP-43 pathology occurs in multiple cell types. Understanding this selectivity is crucial for targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.484, “reason”: “9 token overlaps; entity overlap: pmid, tdp-43”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}